Using implementation science to develop a familial hypercholesterolemia screening program in primary care: The CARE-FH study

•FH screening in primary care practices are acceptable, appropriate, and feasible.•An implementation strategy package was co-developed with primary care stakeholders to improve screening for FH within their practices.•Demonstrating successful screening for FH in primary care practice will help incre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical lipidology 2024-03, Vol.18 (2), p.e176-e188
Hauptverfasser: Jones, Laney K., Romagnoli, Katrina M., Schubert, Tyler J., Clegg, Katarina, Kirchner, H. Lester, Hu, Yirui, Cawley, Dylan, Norelli, Victoria, Williams, Marc S., Gidding, Samuel S., Rahm, Alanna K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•FH screening in primary care practices are acceptable, appropriate, and feasible.•An implementation strategy package was co-developed with primary care stakeholders to improve screening for FH within their practices.•Demonstrating successful screening for FH in primary care practice will help increase the number of individuals identified with FH.•Generalization of the primary care implementation strategy to other settings will improve FH identification nationwide. We designed the Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia (CARE-FH) clinical trial to improve FH screening in primary care and facilitate guideline-based care. The goal was to incorporate perspectives from end-users (healthcare system leaders, primary care clinicians, cardiologists, genetic counselors, nurses, and clinic staff) and improve translation of screening guidance into practice. We partnered with end-users to sequentially define the current state of FH screening, assess acceptability, feasibility, and appropriateness of implementing an FH screening program, and select clinically actionable strategies at the patient-, clinician-, and system-level to be deployed as a package in the CARE-FH clinical trial. Methods informed by implementation science and human centered design included: contextual inquiries, surveys, and deliberative engagement sessions. Screening for FH occurred rarely in primary care, and then only after a cardiovascular event or sometimes due to a family history of high cholesterol or early heart attack. Surveys suggested FH screening in primary care was acceptable, appropriate, and feasible. Reported and observed barriers to screening include insufficient time at patient encounters to screen, cost and convenience of testing for patients, and knowledge regarding causes of dyslipidemia. Facilitators included clear guidance on screening criteria and new therapies to treat FH. These results led to the development of multilevel strategies that were presented to end-users, modified, and then pilot tested in one primary care clinic. A refined implementation strategy package for FH screening was created with a goal of improving FH awareness, identification, and initiation of guideline-based care. https://clinicaltrials.gov/study/NCT05284513?id=NCT05284513&rank=1 Unique Identifier: NCT05284513 [Display omitted]
ISSN:1933-2874
1876-4789
DOI:10.1016/j.jacl.2024.01.001